TY  - GEN 
AU  - Murray, M.
AU  - Antela López, Antonio
AU  - Mills, A.
AU  - Huang, J.
AU  - Jäger, H.
AU  - Bernal, E.
AU  - Lombaard, J.
AU  - Katner, H.
AU  - Walmsley, S.
AU  - Khuong-Josses, M. A.
AU  - Hudson, K.
AU  - Dorey, D.
AU  - Griffith, S.
AU  - Spreen, W.
AU  - Vanveggel, S.
AU  - Shaefer, M.
AU  - Margolis, D.
AU  - Chounta, V.
PY  - 2020
SN  - 1090-7165
UR  - http://hdl.handle.net/20.500.11940/16540
AB  - The phase 3 ATLAS and FLAIR studies demonstrated that maintenance with Long-Acting (LA) intramuscular cabotegravir and rilpivirine is non-inferior in efficacy to current antiretroviral (CAR) oral therapy. Both studies utilized Patient-Reported Outcome...
KW  - Anti-HIV Agents
TI  - Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks
DO  - 10.1007/s10461-020-02929-8
KW  - CHUS
VL  - 24
ER  -